226 results on '"Altman, Alon D."'
Search Results
2. A comparison of synoptic reports and dictated reports to enhance and standardize surgical documentation and quality of care in epithelial ovarian cancer
3. Ovarian Cancer in the Older Manitoban Population—Treatment Tolerance and Cancer-Related Outcomes: A Manitoba Ovarian Cancer Outcomes (MOCO) Group Study
4. Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study
5. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis
6. Perioperative Incidence of Venous Thromboembolism in Patients With Ovarian Cancer Using Four Different Data Collection Methods: A Manitoba Ovarian Cancer Outcomes (MOCO) Group Study
7. Canadian Enhanced Recovery After Surgery (ERAS) Cesarean Delivery Perioperative Management Survey
8. Contributors
9. Venous thromboembolic prophylaxis
10. Gynecologic/Oncology Surgery
11. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples
12. The Canadian Gynecologic Oncology Peri-operative Management Survey: re-examining Enhanced Recovery After Surgery (ERAS) recommendations
13. The Risk of Postoperative Infectious Complications Following Massive Intraoperative Blood Loss During Gynaecologic Laparotomy: Retrospective Cohort Study
14. Response to Multi-Line Chemotherapy in Non-Serous Epithelial Ovarian Cancer
15. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study
16. No. 385-Indications for Pelvic Examination
17. No 385 - Indications de l'examen pelvien
18. Examining the Selection Criteria of Neoadjuvant Chemotherapy Patients
19. Rate of Appendiceal Metastasis with Non-Serous Epithelial Ovarian Cancer in Manitoba
20. Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study
21. Exploring the role of a multidisciplinary hereditary gynecologic oncology clinic in epithelial ovarian cancer risk‐reducing surgical decision‐making practices: A mixed‐methods study
22. Oncologic Outcomes of Surgically Treated Cervical Cancer with No Residual Disease on Hysterectomy Specimen: A 4C (Canadian Cervical Cancer Collaborative) Working Group Study
23. Vulvar postoperative care, gestalt or evidence based medicine? A comprehensive systematic review
24. The Canadian Gynaecologic Oncology Perioperative Management Survey: Baseline Practice Prior to Implementation of Enhanced Recovery After Surgery (ERAS) Society Guidelines
25. Postoperative Infection in the Setting of Massive Intraoperative Blood Loss
26. Enhanced recovery after surgery: implementing a new standard of surgical care
27. Shifting incidence and survival of epithelial ovarian cancer (1995‐2014): A SurvMark‐2 study
28. A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer
29. Referral, Genetic Counselling, and BRCA Testing in the Manitoba High-Grade Serous Ovarian Cancer Population, 2004–2019
30. Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC)
31. sj-docx-1-tam-10.1177_17588359231157633 – Supplemental material for A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer
32. Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high risk endometrial cancers
33. Low-Risk Gestational Trophoblastic Neoplasia in Manitoba: Experience With Alternating Methotrexate and Dactinomycin
34. The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer
35. A population-based study of outcomes in adjuvant radiotherapy for stage II endometrial carcinoma
36. A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
37. Understanding the Experience of Canadian Women Living with Ovarian Cancer through the Every Woman StudyTM
38. Examining the Effects of Time to Diagnosis, Income, Symptoms, and Incidental Detection on Overall Survival in Epithelial Ovarian Cancer: Manitoba Ovarian Cancer Outcomes (MOCO) Study Group
39. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors
40. Understanding the Experience of Canadian Women Living with Ovarian Cancer through the Every Woman Study™
41. Cytotoxic capacity of a novel glycosylated antitumor ether lipid in chemotherapy-resistant high grade serous ovarian cancer in vitro and in vivo
42. Hormone Use After Nonserous Epithelial Ovarian Cancer: Overall and Disease-Free Survival
43. Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.
44. Extra-uterine endometrial stromal sarcoma of the left adnexa and distal ureter: A case report
45. Guidelines for vulvar and vaginal surgery: Enhanced Recovery After Surgery Society recommendations
46. Hereditary Angioedema Managed with Low-Dose Danazol and C1 Esterase Inhibitor Concentrate: A Case Report
47. New approaches to cancer care in a COVID-19 world
48. Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery
49. International validation of Enhanced Recovery After Surgery Society guidelines on enhanced recovery for gynecologic surgery
50. Uterine Inversion as a Result of a Large Prolapsed Carcinosarcoma of the Uterus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.